RedHill Biopharma Provides Q3/2020 Results and Highlights, Including 300% Talicia Prescription Growth

Go back to RedHill Biopharma Provides Q3/2020 Results and Highlights, Including 300% Talicia Prescription Growth
REDHILL BIO SP ADS (NASDAQ: RDHL) Delayed: 0.43 -0.03 (6.52%)
Previous Close $0.46    52 Week High $16.54 
Open $0.46    52 Week Low $8.10 
Day High $0.47    P/E N/A 
Day Low $0.41    EPS $0.00 
Volume 149,295